If you work anywhere near an ED, ICU, poison center, pharmacy, public-health office, or addiction-medicine clinic, this one is worth watching closely: the problem is not simply “psychedelics.” The problem is mislabeled products, hidden chemistry, and an unregulated edible market that can turn a candy-like product into an unpredictable toxic exposure. For a deeper look at this exact product category, see Are Psilocybin Mushroom Gummies Safe? What Toxicology Testing Reveals.

A recent analysis of commercially available “magic mushroom” edibles sold in Portland found a striking pattern: products marketed as psychedelic mushroom gummies did not contain detectable psilocybin, while several contained undisclosed active ingredients [A]. At the same time, the Diamond Shruumz outbreak showed how mushroom-containing products can move from retail shelves to poison-center reports, hospitalizations, ICU care, and death. This finding closely overlaps with Psilocybin Gummies Contaminated with Dangerous Synthetic Compounds, which explains why hidden chemistry matters clinically.

Here’s the toxicology roundup.

Already covered on MedicalToxic.com:

• Psilocybin Gummies Contaminated with Dangerous Synthetic Compounds

• Diamond Shruumz™ Brand: A Growing Public Health Concern

• Mushroom Poisoning in the TikTok Era: When Foraging Goes Wrong

• Synthetic Marijuana Unmasked: The Deadly Truth Behind K2, Spice, and Paper Dope

1) Oregon Analysis: “Magic Mushroom” Edibles Contained No Detectable Psilocybin

Researchers tested 12 commercially available products sold as “magic mushroom” edibles in Portland, Oregon. The product group included 11 gummies and one chocolate bar [B]. Despite mushroom-style marketing, psychedelic imagery, and product claims suggesting natural mushroom effects, laboratory testing found no detectable psilocybin in any of the 12 products.

Muscimol, the psychoactive compound commonly associated with Amanita muscaria, was also not detected.

Toxicology lens:
This is not a minor labeling problem. If a person believes they are taking psilocybin but the product contains something else, the exposure history becomes unreliable from the start. That affects risk assessment, poison-center triage, emergency evaluation, and patient counseling.

Practical point:
For clinicians, “the label says mushroom gummy” should not be treated as a definitive exposure history.

2) Seven Products Contained Undisclosed Active Ingredients

Seven of the tested products contained active ingredients that were not properly disclosed on product labels. Reported undisclosed substances included caffeine, hemp or cannabis-related extracts, kava extract, and synthetic psychedelic compounds.

Some products contained no detectable active ingredient at all, meaning they appeared pharmacologically closer to ordinary confectionery than to a verified psychedelic product.

Toxicology lens:
The danger is uncertainty. A product may be inactive, contaminated, adulterated, or substituted with a synthetic psychoactive compound. That means the clinical picture may not match the product name, packaging, or consumer expectation.

Practical point:
When evaluating acute symptoms after mushroom-edible use, ask about co-ingestants, brand, packaging, lot information, timing, dose, source, and whether others used the same product.

3) Hidden “Syndelics”: Synthetic Psychedelics in Consumer Gummies

Two gummies contained synthetic psychoactive tryptamines described by researchers as “syndelics,” meaning synthetic psychedelics designed to mimic or modify the effects of naturally occurring psychedelic compounds.

These compounds are not the same as verified psilocybin from Psilocybe mushrooms. Their human toxicity profile, dose-response relationship, interaction risk, and long-term safety may be poorly characterized outside controlled research settings. For broader clinical context on evidence-based psychedelic use versus risky consumer products, read Psychedelics in 2025: What’s Evidence-Based, What Isn’t, and How to Counsel Patients.

Toxicology lens:
A synthetic tryptamine in an unregulated edible is a very different exposure than a supervised, known-dose psilocybin session. Unknown potency and hidden ingredients create risk for unexpected neuropsychiatric, cardiovascular, or neurologic effects.

Practical point:
If a patient presents after “mushroom gummy” ingestion with agitation, confusion, seizure, sedation, vomiting, abnormal vital signs, or mixed toxidrome features, consider that the product may contain undisclosed synthetic compounds.

4) Cannabis Extract and Kava Complicate the Exposure Picture

The analysis also identified products containing cannabis-related compounds and kava extract. These substances can affect the central nervous system and may interact with other psychoactive compounds, sedatives, alcohol, psychiatric medications, or underlying medical conditions.

Kava is often marketed as natural or calming, but “natural” does not mean risk-free. Cannabis-related compounds may also change the clinical picture, especially when the consumer does not expect cannabinoid exposure.

Toxicology lens:
Undisclosed mixtures are clinically important because the combined effect may differ from any single ingredient. Sedation, anxiety, panic, altered perception, impaired coordination, vomiting, or unexpected behavioral symptoms may reflect more than one active compound.

Practical point:
Do not assume one ingredient explains the presentation. Unregulated edibles may be multi-compound exposures.

5) Diamond Shruumz: When Mushroom Products Became a National Safety Signal

The Diamond Shruumz outbreak showed how quickly mushroom-containing products can become a public-health concern [C]. Reports included severe illness across multiple U.S. states, hospitalizations, ICU-level care, intubations, and deaths under investigation [D]. MedicalToxic has covered this warning signal in detail in Diamond Shruumz™ Brand: A Growing Public Health Concern.

The product line was recalled, and federal and state investigations identified multiple chemical constituents in tested products [E]. The outbreak became a major reminder that attractive packaging, wellness language, or “microdosing” claims do not guarantee safety.

Toxicology lens:
This is the same pattern clinicians already recognize from counterfeit medications, adulterated supplements, mislabeled cannabinoids, and novel psychoactive substances: the marketplace moves faster than verification.

Practical point:
When cases cluster around a branded product, poison centers, public-health agencies, and clinicians should preserve packaging details and report suspected adverse events.

6) Regulated Psilocybin Therapy Is Not the Same as Unregulated Gummies

One of the most important public-health distinctions is between regulated psychedelic therapy and retail psychoactive edibles. Regulated care involves screening, controlled dosing, trained supervision, defined protocols, and emergency planning. Unregulated gummies may contain no psilocybin, hidden synthetic compounds, cannabis extract, kava, or other undisclosed substances.

Toxicology lens:
Conflating these categories is clinically misleading. The issue is not simply “psychedelics good” or “psychedelics bad.” The issue is known-dose, supervised, regulated exposure versus unknown-dose, mislabeled, multi-compound exposure. This distinction is also important when interpreting microdosing trends, as discussed in Hidden Dangers of Microdosing Psilocybin: New Research Reveals Unexpected Risks.

Practical point:
For patient counseling, use precise language: regulated psilocybin services are not equivalent to smoke-shop, gas-station, or online mushroom gummies.

Practical Takeaways

• The label is not always the exposure: a product marketed as a mushroom gummy may not contain psilocybin and may contain undisclosed compounds.

• Zero psilocybin does not mean zero risk: a product can lack psilocybin while still containing synthetic psychedelics, cannabis-related compounds, kava, or other active ingredients.

• Hidden ingredients create toxicology uncertainty: unknown dose, unknown compound identity, and unknown interactions can complicate emergency assessment.

• Diamond Shruumz should remain a warning signal: severe illness, hospitalization, and deaths linked to mushroom-containing products show why these products deserve public-health attention [F].

• Counsel carefully: do not equate regulated psychedelic therapy with unregulated retail edibles.

• Report suspected cases: clinicians should consider poison-center consultation and adverse-event reporting when patients present after consuming mushroom gummies, microdosing products, or psychedelic edibles.

For a broader public-facing prevention angle, Mushroom Poisoning in the TikTok Era: When Foraging Goes Wrong explains why mushroom-related exposures require careful risk communication.

References

1. Oregon State University. Analysis of “magic mushroom” edibles finds no psilocybin but many undisclosed active ingredients. Published September 11, 2025.

2. van Breemen RB, Simchuk D, Fritzsche B, Huson D, Kuzdzal SA, Ferguson J. Active Constituents of Psilocybin Mushroom Edibles. JAMA Network Open. 2025;8(9):e2531345. doi:10.1001/jamanetworkopen.2025.31345.

3. Centers for Disease Control and Prevention. Severe Illness Potentially Associated with Consuming Diamond Shruumz™ Brand Chocolate Bars, Cones, and Gummies. Updated November 14, 2024.

4. Rumph JT, et al. Severe Illness Associated with Eating Mushroom-Containing Chocolate Products — United States, January–October 2024. MMWR Morb Mortal Wkly Rep. 2026.

5. U.S. Food and Drug Administration. Investigation of Illnesses: Diamond Shruumz-Brand Chocolate Bars, Cones, & Gummies. FDA outbreak investigation page.

6. U.S. Food and Drug Administration. Prophet Premium Blends Recalls Diamond Shruumz Products Because of Possible Health Risk. FDA recall announcement. Published June 28, 2024.